# Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)

> **NCT01757574** · PHASE4 · WITHDRAWN · sponsor: **Johns Hopkins University**

## Conditions studied

- Chronic Inflammatory Demyelinating Neuropathy

## Interventions

- **DRUG:** Alemtuzumab infusion

## Key facts

- **NCT ID:** NCT01757574
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-11
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** At the request of the global principal investigator, no subjects were enrolled in this study at any site.
- **Last updated:** 2017-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01757574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01757574, "Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01757574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*